TY - JOUR
T1 - Improving tumor budding reporting in colorectal cancer
T2 - a Delphi consensus study
AU - Haddad, Tariq Sami
AU - Lugli, Alessandro
AU - Aherne, Susan
AU - Barresi, Valeria
AU - Terris, Benoît
AU - Bokhorst, John Melle
AU - Brockmoeller, Scarlet Fiona
AU - Cuatrecasas, Miriam
AU - Simmer, Femke
AU - El-Zimaity, Hala
AU - Fléjou, Jean François
AU - Gibbons, David
AU - Cathomas, Gieri
AU - Kirsch, Richard
AU - Kuhlmann, Tine Plato
AU - Langner, Cord
AU - Loughrey, Maurice B.
AU - Riddell, Robert
AU - Ristimäki, Ari
AU - Kakar, Sanjay
AU - Sheahan, Kieran
AU - Treanor, Darren
AU - van der Laak, Jeroen
AU - Vieth, Michael
AU - Zlobec, Inti
AU - Nagtegaal, Iris D.
N1 - Funding Information:
This project has received funding from the Dutch Cancer Society, project number 10602/2016-2.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/9
Y1 - 2021/9
N2 - Tumor budding is a long-established independent adverse prognostic marker in colorectal cancer, yet methods for its assessment have varied widely. In an effort to standardize its reporting, a group of experts met in Bern, Switzerland, in 2016 to reach consensus on a single, international, evidence-based method for tumor budding assessment and reporting (International Tumor Budding Consensus Conference [ITBCC]). Tumor budding assessment using the ITBCC criteria has been validated in large cohorts of cancer patients and incorporated into several international colorectal cancer pathology and clinical guidelines. With the wider reporting of tumor budding, new issues have emerged that require further clarification. To better inform researchers and health-care professionals on these issues, an international group of experts in gastrointestinal pathology participated in a modified Delphi process to generate consensus and highlight areas requiring further research. This effort serves to re-affirm the importance of tumor budding in colorectal cancer and support its continued use in routine clinical practice.
AB - Tumor budding is a long-established independent adverse prognostic marker in colorectal cancer, yet methods for its assessment have varied widely. In an effort to standardize its reporting, a group of experts met in Bern, Switzerland, in 2016 to reach consensus on a single, international, evidence-based method for tumor budding assessment and reporting (International Tumor Budding Consensus Conference [ITBCC]). Tumor budding assessment using the ITBCC criteria has been validated in large cohorts of cancer patients and incorporated into several international colorectal cancer pathology and clinical guidelines. With the wider reporting of tumor budding, new issues have emerged that require further clarification. To better inform researchers and health-care professionals on these issues, an international group of experts in gastrointestinal pathology participated in a modified Delphi process to generate consensus and highlight areas requiring further research. This effort serves to re-affirm the importance of tumor budding in colorectal cancer and support its continued use in routine clinical practice.
KW - Colorectal cancer
KW - Delphi study
KW - ITBCC
KW - Tumor budding
U2 - 10.1007/s00428-021-03059-9
DO - 10.1007/s00428-021-03059-9
M3 - Journal article
C2 - 33650042
AN - SCOPUS:85101859076
VL - 479
SP - 459
EP - 469
JO - Virchows Archiv
JF - Virchows Archiv
SN - 0945-6317
IS - 3
ER -